Cancer clinical trials in the region Auvergne-Rhône-Alpes
495 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT04585750
#2023-504251-27-00
Phase 2 cohorte de patientes atteintes d'un cancer de l'ovaire
Required histologic types
Epithelial ovarian cancer
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded genetic anomalies
KRAS G12C
KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2
Lung cancer
#NCT04585750
#2023-504251-27-00
Phase 2 cohorte de patients atteints de cancer du poumon
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded genetic anomalies
KRAS G12C
KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2
Breast cancer
#NCT04585750
#2023-504251-27-00
Phase 2 cohorte de cancer du sein
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded genetic anomalies
KRAS G12C
KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2
Endometrial cancer
#NCT04585750
#2023-504251-27-00
Phase 2 cohorte de patients atteints d'un cancer de l'endomètre
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded genetic anomalies
KRAS G12C
KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2
Prostate cancer
#NCT06990880
#2025-521581-10
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Chemotherapy
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
GlaxoSmithKline
Phase 1 / Phase 2
Breast cancer
#NCT05768139
#2023-000442-41
Cohortes combinaison extension de dose cancer du sein RH+
Required HER2 statuses
HER2 Negative
HER2 Low
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Eli Lilly et compagnie
Phase 1 / Phase 2
Prostate cancer
#NCT07226986
#2025-521859-23-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required PSMA PET Scan statuses
PSMA PET Positive
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Hormone therapy
4 recruiting sites
Novartis
Phase 1 / Phase 2
Lymphoma
#NCT06137144
Module 1 Cohorte 2
Required histologic types
Hodgkin lymphoma
Required disease stage
Disseminated (stage III and IV)
Required number of previous lines of therapy
None
Required previous treatments
Chemotherapy
3 recruiting sites
AstraZeneca
Phase 1 / Phase 2
Lymphoma
#NCT06137144
Module 2 Cohorte 1
Required histologic types
Hodgkin lymphoma
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
AstraZeneca
Phase 1 / Phase 2
Lymphoma
#NCT06137144
Module 1 Cohorte 3
Required histologic types
T cell lymphoma
Required histologic sub types
Peripheral T cell lymphoma
Required disease stage
Disseminated (stage III and IV)
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
AstraZeneca